MCK · 10-Q · 2026Q2 · Full report

Pharmaceutical Distribution Volumes

MCKESSON CORP · 2026-08-05 · Importance 37 · Surprise 32

North American Pharmaceutical revenue increased $4.0 billion, or 5%, year over year to $86.8 billion. Higher volumes from institutional healthcare providers and retail national account customers were the principal growth drivers. The segment’s operating profit also benefited from higher pharmaceutical distribution volumes across the segment, while the prior-year Rite Aid bankruptcy charge did not recur.

Key facts

• North American Pharmaceutical revenues increased $4.0 billion or 5% for the three months ended June 30, 2026 compared to the same prior year period; within the segment sales in the U.S. increased $3.7 billion primarily due to higher volumes from institutional and retail national account customers partially offset by branded pharmaceutical price decreases and branded to generic conversions. source
• Other segment expense, net for North American Pharmaceutical included a provision for bad debts of $189 million during the three months ended June 30, 2025 related to the bankruptcy of Rite Aid. source
• Operating profit for the North American Pharmaceutical segment increased for the three months ended June 30, 2026 largely due to higher pharmaceutical distribution volumes and absence of the prior year Rite Aid bankruptcy impact, partially offset by higher operating expenses to support volume growth. source